A real life study evaluating efficacy and safety of combination of Carfilzomib, Lenalidomide and Dexamethasone in patients with relapsed and refractory multiple myeloma
Latest Information Update: 12 Oct 2022
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 01 Oct 2022 Results assessing the efficacy and safety of carfilzomib, in combination with lenalidomide-dexamethasone as salvage regimen in patients with refractory multiple myeloma, published in the Clinical Lymphoma, Myeloma & Leukemia.
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association
- 04 Jun 2019 Results (n=41) assessing efficacy of Carfilzomib-Lenalidomide-Dexamethasone in multiple myeloma patients, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).